DISCLAIMER
The information and materials accessed through or made available for use on any of our Sites, including, any information about diseases, conditions, treatments, or medicines, are for informational purposes only. The Content is not intended to be and is not a substitute for professional medical advice, diagnosis, or treatment, and your participation on our Sites does not create a healthcare professional-patient relationship. You should consult a doctor or other qualified health care professional regarding any questions you have about your health or before making any decisions related to your health or wellness. Call your doctor or 911 immediately if you think you may have a medical emergency.compose your message
message sent
email sent successfully
Trusted Resources: News & Events
Latest announcements and gatherings
Kids Who Need Sickle Cell Meds Don’t Always Get Them
Less than a fifth of U.S. children with sickle cell anemia are getting the antibiotics that could save their lives, a new study finds.
“Longstanding recommendations say children with sickle cell anemia should take antibiotics daily for their first five years of life,” the study’s lead author, Sarah Reeves, said in a news release from Michigan Medicine.
These antibiotics can protect the children against potentially deadly infections, Reeves said. She’s an epidemiologist with the Child Health Evaluation and Research Center at the University of Michigan Medical School.
Bacterial infections are a major health threat for children with sickle cell anemia, but taking daily antibiotics can reduce that risk by 84 percent, according to the study.
However, the researchers found that just 18 percent of children with the blood disorder were taking antibiotics daily.
+myBinderRelated Content
-
education & researchPotential therapeutic action of nitrite in sickle cell diseaseSickle cell disease is caused by a mutan...
-
education & researchAssociation of Antibiotic Choice With Hospital Length of Stay and Risk Factors for Readmission in Patients With Sick...Study objective: We determine the assoc...
-
news & eventsbluebird bio Announces Publication of Case Study on First Patient with Severe Sickle Cell Disease Treated with Gene ...Patient treated with LentiGlobinTM drug ...
-
news & eventsLa Jolla Pharmaceutical company announces initiation of pivotal clinical study of LJPC-401 in patients with beta tha...La Jolla Pharmaceutical company today an...
-
news & eventsNew Sickle Cell Disease Research Shows Improved Patient OutcomesEmerging therapies and promising new ins...
-
news & eventsA new Sickle Cell Disease Drug Holds Much Promise but Most Sufferers Won’t be Able to Afford itThe regulatory approval of a groundbreak...
-
news & eventsExperimental Gene Therapy Reverses Sickle Cell Disease for YearsA study of an investigational gene thera...
send a message
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.